70 results about "Hippocampal region" patented technology

The invention belongs to the technical field of food microorganisms, and relates to lactobacillus plantarum and application thereof in preparation of products for relieving insomnia. The preservation number of the lactobacillus plantarum is GDMCC No: 65061. The lactobacillus plantarum can be applied to efficient fermentation of spina date seed juice, the content of GABA, polypeptide, total phenols and total flavonoids in the spina date seed juice is increased, and the content of spinosin, 6 ''-feruloyl spinosin, jujuboside A, jujuboside B and betulinic acid is increased; the reduction of whole brain coefficient and the increase of liver coefficient caused by long-term insomnia are relieved, the bad condition caused by long-term insomnia in a hippocampus DG region in the brain of the mouse is improved, the sleep time of the mouse is prolonged, and the insomnia symptom of the mouse is relieved; the content of inhibitory neurotransmitters 5-hydroxytryptamine, melatonin and gamma-aminobutyric acid in the hypothalamus of the mouse is increased, the content of excitatory neurotransmitter glutamic acid is reduced, and the reduction of organism immunity and oxidative stress of brain tissues caused by insomnia are relieved.

The invention discloses application of walnut peptide in preparation of a medicine for treating or preventing cognitive impairment of diabetes mellitus. The preparation process of the walnut peptide is as follows: after walnut protein is subjected to enzymolysis by alkaline protease, the molecular weight cut-off is 1t; and separating by using a 3kDa ultrafiltration tube to obtain the walnut peptide. The walnut peptide can effectively reduce the blood sugar level of a diabetic model mouse, regulate the disorder effect of blood fat, relieve brain tissue oxidative damage and hippocampal neuroinflammation damage of the diabetic model mouse, and improve learning and memory damage. The compound can be used for preparing medicines for treating or preventing cognitive impairment of diabetes mellitus.

The invention provides a circular RNA circ0004801 and an application of the circular RNA circ0004801 in treatment of an Alzheimer's disease. The nucleotide sequence of the circular RNA circ0004801 is as shown in SEQ ID NO: 1 (Sequence Identity Number 1). The expression of the circular RNA circ0004801 in the hippocampal tissue of the AD mouse is obviously up-regulated, and the circular RNA circ0004801 is used as a'sponge 'of miR-7688-5p and plays a role by adjusting the TTBK1 expression and tau phosphorylation level. By knocking down the circular RNA circ0004801, the spatial learning and memory of a 3 * Tg mouse can be obviously improved, and the tau protein phosphorylation level of a hippocampus region and the NFTs density of a hippocampus DG region can be obviously reduced. Therefore, the circular RNA circ0004801 and the miR-7688-5p can be used as new targets for treating the AD (Alzheimer's disease). According to the invention, it is found for the first time that circular RNA circ0004801 regulates TTBK1 through a ceRNA mechanism, so that excessive phosphorylation of tau is driven, and a new molecular target is provided for AD early intervention treatment based on circRNA and miRNA.

The application discloses a new use of Leonurine or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating radiation-induced brain injury, specifically, providing a safe and effective therapeutic drug for iron death, neuroinflammation, neuron damage and lipid metabolism disorder accompanying the radiation-induced brain injury, solving the technical problem of lack of specific treatment means in the prior art, and having a wide clinical application prospect. Experiments adopt a C57BL / c mouse 30 Gy whole brain X-ray radiation model, and results show that Leonurine can significantly improve the body weight decrease and survival rate of the model mice, reduce the serum IL-6 and IFN-alpha levels, inhibit the activation of microglial cells in the cerebral cortex and hippocampus, protect and repair damaged neurons, and improve the ultrastructure of mitochondria and synapses; meanwhile, the expression of GPX4 and SLC7A11 proteins in the brain tissue is up-regulated, the GSH content is increased to inhibit iron death, and the levels of GPE, GPS and GPC related to lipid metabolism are restored.

The invention discloses armillariella mycelium polysaccharide ATMP capable of improving cognitive impairment and a preparation method and application of the armillariella mycelium polysaccharide ATMP. The polysaccharide is composed of two components, and the molecular weights of the two components are 2.30 * 10 < 4 > Da and 4.56 * 10 < 5 > Da respectively; the monosaccharide composition comprises mannose (Man), glucose (Glc) and galactose (Gal), and the molar ratio of the mannose (Man) to the glucose (Glc) to the galactose (Gal) is 1: 16.64: 1.96. Animal experiment results show that the armillariella mycelium polysaccharide ATMP can improve cognitive impairment induced by lipopolysaccharide (LPS) by improving the spatial memory ability of mice, repairing the disorder state and deletion injury of neurons in a hippocampal region and relieving neuroinflammatory response, so that the obvious neuroprotective effect is achieved. As a natural brain-benefiting active component, the armillariella tabescens mycelium polysaccharide ATMP has a wide application prospect in the related fields of brain health.

The invention discloses a traditional Chinese medicine composition for improving memory and concentration and a preparation method thereof, and relates to the technical field of traditional Chinese medicine formulas. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 12-22 parts of fructus alpiniae oxyphyllae, 15-25 parts of radix astragali, 8-16 parts of ginseng, 10-20 parts of walnuts, 10-20 parts of radix puerariae, 6-14 parts of cornel pulp, 8-18 parts of radix rehmanniae, 10-20 parts of Chinese wolfberry fruits, 15-25 parts of spina date seeds, 8-16 parts of polygala tenuifolia, 6-14 parts of rhizoma acori graminei and 4-10 parts of earthworms. According to the traditional Chinese medicine composition for improving memory and concentration and the preparation method of the traditional Chinese medicine composition, polygala ketone contained in polygala tenuifolia can specifically up-regulate hippocampal BDNF expression and doubly repair memory pathway damage caused by alcohol, volatile asarone in acorus gramineus can penetrate a blood brain barrier, and the volatile asarone is compatible with polygala tenuifolia, so that the nerve stimulation threshold value of a single component can be reduced, the intelligence promoting effect can be improved, and the traditional Chinese medicine composition can be used for improving memory and concentration. The earthworm extract can inhibit the activity of lactic dehydrogenase in the brain, and the synergistic effect mechanism of the polygala tenuifolia, the rhizoma acori graminei and the earthworm can also play a role in preventing and treating the Alzheimer's disease.

Methods and compositions for the treatment of cognitive disorders are provided herein.The present disclosure generally relates to the field of methods for delivering gene therapy to the entorhinal / hippocampal region accurately and safely to treat cognitive disorders and other diseases of the central nervous system (CNS).The present disclosure describes the specific parameters for targeting this network of brain regions, including accurate anatomical target, vector concentration and vector volume, and the subject may be at risk of suffering from a condition selected from Alzheimer's disease (AD), mild cognitive impairment, pre-symptomatic AD, frontotemporal dementia, or Lewy body dementia.

The application discloses an application of Campanula medium in treatment of perimenopausal depression, and a method is as follows: Campanula medium is added into 10 times of distilled water in weight, decocted for 1 h and filtered, residues are added with 8 times of distilled water, and then decocted for 1 h and filtered, and filtrates are combined, and concentrated into 1 g / mL of medicinal liquid according to medicinal material, so that Campanula medium medicinal liquid is obtained. According to the experimental result, Campanula medium can improve the depression and anxiety behavior of PMD model mice. Campanula medium can improve the hippocampus tissue morphology and structure of the PMD model mice, increase the neuron Nissl body abundance of the hippocampus, promote the ER-BDNF-TrkB path, improve the monoamine neurotransmitter level, correct the HPA axis hyperactivity, and thus improve the depression behavior.

This invention discloses a method for identifying and processing abnormal hippocampal atrophy in functional MRI images of the brain, comprising: acquiring functional MRI image data of the brain to be processed; preprocessing the functional MRI image data of the brain to obtain preprocessed functional MRI image data of the brain; extracting the hippocampal region from the preprocessed functional MRI image data of the brain; constructing a three-dimensional image of the hippocampus based on the hippocampal region; performing feature extraction on the three-dimensional image of the hippocampal region based on a deep learning network to obtain feature extraction results; and classifying and identifying abnormal atrophy of the hippocampal region according to the feature extraction results to obtain classification and identification results.

This invention discloses the application of burdock root polysaccharide in the preparation of drugs for treating cognitive impairment, belonging to the field of traditional Chinese medicine technology. Experiments demonstrate that burdock root polysaccharide can improve cognitive impairment and independent exploration ability in D-galactose-induced cognitive impairment model mice, increase superoxide dismutase activity in mouse serum, reduce malondialdehyde content, decrease the content of interleukin-1β and tumor necrosis factor-α in the hippocampus of mouse brains, and alleviate the loss of neurons in the hippocampus of cognitive impairment model mice, thereby achieving a neuroprotective effect and demonstrating a good therapeutic effect on cognitive impairment. This provides a new approach for developing drugs related to the treatment of cognitive impairment.

The invention relates to an exosome for targeting a central nervous system delivery reagent. Protein for targeting the central nervous system on the exosome is one or more of membrane protein SIRP alpha, membrane protein MCAM and active fragments thereof. The exosome can efficiently target a central nervous system, can target a hippocampal region and a hypothalamic region, can deliver bioactive substances to the center and exert functions, and has good biocompatibility and biological safety.

The invention relates to Witzia ciliaris capable of regulating mood health and relieving anxiety and an application of the Witzia ciliaris. The Witzia ciliaris is separated from a healthy human excrement sample. According to the present invention, the Witzia ciliata KY009 can regulate the levels of 5-hydroxytryptamine, brain-derived neurotrophic factors and cortisol so as to provide the anti-depression effect, can significantly reduce the contents of hippocampal proinflammatory factors such as IL-1beta, IL-6 and IFN-alpha, and has the neuroinflammation inhibition activity. The strain and the composition thereof can be used for preparing medicines for treating depression, functional foods for relieving depressive mood and health-care products for improving mood, play a therapeutic role by correcting immune imbalance state of a body and regulating neuroinflammation, and provide a new microbial intervention strategy for treatment of depression and related mood disorders.

The invention provides traditional Chinese medicine compound essential oil and application thereof in preparation of anti-depression products, and relates to the technical field of traditional Chinese medicine essential oil pharmacy. The traditional Chinese medicine compound essential oil is prepared from 3-15 parts of benzoin essential oil, 2-10 parts of China rose essential oil, 2-10 parts of immature bitter orange essential oil, 1-8 parts of amomum cardamomum essential oil and 1-8 parts of fennel essential oil. The traditional Chinese medicine compound essential oil disclosed by the invention is administered in a sniffing manner, and improves cerebral depression symptoms by stimulating olfactory nerves and influencing cerebral cortex edges and neurotransmitters. After a CUMS depression animal model is treated by the traditional Chinese medicine compound essential oil disclosed by the invention, the symptom of pleasant sensation disappearance is well reversed and improved, and the state of animal movement reduction and the behavior state of despair and struggling abandoning of the depression animal model are obviously improved; meanwhile, the levels of DA, 5-HT and NE in brain tissues of the depression animal model are remarkably improved, and the pathological change of the brain-sea horse area of the depression animal model is remarkably improved. The traditional Chinese medicine compound essential oil disclosed by the invention can be used for preparing medicines for aromatherapy, has no adverse reaction and high acceptability, and provides a new way for treating depression.

The present invention provides a basis for using soluble fiber, particularly compositions comprising Agave fructans, to prevent or treat the accumulation of lipids, particularly ceramides in the liver and brain and lipofuscin in the liver, improving the overall integrity of both organs, with treatment being feasible to prevent fatty liver disease and also prevent Alzheimer's disease (AD). In the present invention, we analyze alterations in lipid metabolism in the liver and ceramide production in the brain of transgenic mice (APP / PS1, TG) for AD. Our results indicate that microvesicular lipid accumulation within hepatocytes is increased in TG mice compared to the control group. Furthermore, in the brains of TG mice, a greater accumulation of ceramides is observed in the somatosensory cortex and entorhinal cortex; in the CA1 region of the hippocampus and in the motor cortex, no significant increase was observed when compared to the control group.

The invention discloses an N-methyl-D-aspartic acid receptor NR2B subunit interference peptide and an application of the N-methyl-D-aspartic acid receptor NR2B subunit interference peptide. Through reasonable design and synthesis, the interference peptide can be specifically combined with endogenous neurotoxic metabolite quinolinic acid (QA), and the combination between the QA and NR2B is blocked in a competitive mode, so that the NR2B-mediated excitatory neurotoxic reaction is selectively inhibited. The polypeptide can remarkably reverse neuron damage and shows an excellent nerve protection effect. In an obesity-related cognitive impairment model and an Alzheimer's disease mouse model, the interference peptide recovers neuronal synaptic injury in a hippocampus region by blocking a QA-NR2B signal channel, effectively improves cognitive hypofunction, and provides an innovative intervention strategy for prevention and treatment of neurodegenerative diseases.

The invention belongs to the technical field of medicines, and particularly relates to preparation of CD73 positive NK cells of umbilical cord blood from different starting sources and application of the CD73 positive NK cells to treatment of Alzheimer's disease. The CD73 + NK cells differentiated from different initial cell types (CD34 positive cells, CD3 negative / CD56 positive cells and CD56 negative cells) of umbilical cord blood are studied, it is found that all the initial cell types of umbilical cord blood sources can be differentiated into the CD73 + NK cells, 34 +-73-NK cells show a higher growth rate, 56-73-NK cells show higher cytotoxicity, and the CD73 + NK cells can be differentiated into the CD73 + NK cells. And the overall effect of the 56-73-NK cell is superior to that of the 34 < + >-73-NK cell. Further research shows that the CD73 + NK can inhibit activation of STZ injection mouse hippocampal microglia and astroglia, so that the neuroinflammation of the hippocampal is reduced, and a new solution is expected to be provided for treatment of AD.

The invention discloses a composite microneedle with bacterial outer membrane vesicles loaded with active ingredients as well as a preparation method and application of the composite microneedle. The composite microneedle is prepared from the bacterial outer membrane vesicles and the active ingredients loaded in the bacterial outer membrane vesicles, the bacterial outer membrane vesicles are derived from mucus eubacterium, the active ingredient is cycloastragenol, and the composite microneedle has a transdermal delivery function and delivers the active ingredient to a target tissue in a targeted manner. The method comprises the following steps: firstly, encapsulating cycloastragenol into mucus eubacterium outer membrane vesicles through a co-incubation or active drug loading technology to form a composite nano-carrier; the EL-OMVs-CAG compound prepared by the invention has good biocompatibility and blood brain barrier penetrating ability, and can target a central nervous system, regulate the activity of microglial cells, inhibit neuroinflammatory response and reduce synaptic loss and neuronal apoptosis in a hippocampal region, so that cognitive function impairment caused by operation and anesthesia is improved.

The invention relates to a construction method and application of a rapid aging animal model. According to the invention, the C5a protein is injected into the hippocampus of an animal in a brain stereotactic manner, so that the rapid aging animal model is successfully constructed. The rapid aging animal model construction method provided by the invention has high repeatability, and the rapid aging animal model can be efficiently and stably prepared; moreover, the rapid aging animal model constructed according to the method disclosed by the invention shows obvious and stable learning and memory disorder and aging-related phenotypes, including reduction of learning and memory ability, increase of aging marker level, damage of synapse-related protein and the like, has high representativeness, and can be applied to the rapid aging animal model. Therefore, the method is not only suitable for pathological mechanism research of senescence and related diseases or symptoms, but also provides a powerful tool for drug development of senescence related diseases or symptoms (such as cognitive hypofunction caused by senescence), and shows a good industrial application prospect.

The invention discloses application of alpha-cyperone in preparation of drugs for treating sepsis, a mouse sepsis model is constructed by adopting a cecum ligation perforation (CLP) method, and through sepsis symptom clinical scoring and open field experiments, it is found that alpha-cyperone reverses the sepsis symptom, recovers the weight of a mouse and reduces the death rate of the mouse; through a Q-PCR (Quantitative Polymerase Chain Reaction) method, a Western Blot method and the like, the alpha-cyperone is found to alleviate oxidative stress and cell inflammatory factor expression, alleviate brain synaptic dysfunction and alleviate nerve cell pyroptosis in a hippocampus area; animal experiments find that alpha-cyperone has the function of improving sepsis-related encephalopathy, and in a word, a new way is provided for sepsis treatment.

The invention relates to the technical field of Gaucher disease treatment, in particular to application of nicotine in preparation of drugs for relieving, adjuvant therapy or treatment of Gaucher diseases. The invention reveals for the first time that nicotine can enhance mitochondrial autophagy mediated by a PGC1 alpha / Parkin pathway by reducing accumulation of glucosylceramide and up-regulating protein expression of PGC1 alpha and Synaptophysin in a hippocampal region, also improves synaptic function and various neurotransmitter levels, enhances learning memory and application ability, and further improves neurodegenerative diseases caused by Gaucher disease.

The invention provides application of a salidroside derivative in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion, and belongs to the technical field of biological medicine. The invention discloses application of a salidroside derivative SHPL-49 in preparation of a medicine for preventing and / or treating cognitive impairment caused by cerebrovascular lesion. The SHPL-49 can effectively improve the learning and memory functions after brain injury, recover the exercise coordination ability, relieve corpus callosum region myelin sheath loss above the hippocampus region and further protect the brain-sea horse region synapses. The SHPL-49 has the efficacy of treating the vascular cognitive impairment and the vascular dementia. According to the application, the medical application of the SHPL-49 is widened, and a new way is provided for treating cognitive impairment diseases caused by cerebrovascular lesion.

The invention provides an experimental method for verifying the curative effect of retinoic acid on schizophrenia, which comprises the following steps: step 1, selecting two groups of pregnant SD rats, injecting Poly I: C into tail veins of one group of SD rats after 9.5 days of pregnancy according to the standard of 10 mg / kg, and taking male offspring rats as schizophrenia model group rats; the other group of SD rats are intravenously injected with equal-volume normal saline at the tail after pregnancy 9.5 days, and the male offspring rats are the control group; 2, the model components are divided into two groups, retinoic acid is fed to one group 45 days after birth according to the standard of 3 mg / kg / day, an equal amount of placebo is injected to the other group, and an equal amount of placebo is injected to the control group; step 3, carrying out behavioral detection experiments on the three groups of rats in the step 2; and 4, implanting electrodes into hippocampal CA1 regions of the three groups of rats in the step 2, and recording and analyzing electroencephalogram activities of the three groups of rats. The experimental method provided by the invention proves that the retinoic acid has good application value in preparation of the schizophrenia medicine.

The invention relates to a pharmaceutical application of a GLP-1 receptor stimulant semeglutide, in particular to a novel pharmaceutical application of the GLP-1 receptor stimulant semeglutide, namely the semeglutide regulates hippocampal mitochondrial kinetics and mitochondrial autophagy balance by activating a phosphatidylinositol 3-kinase (PI3K) / protein kinase B (Akt) signal channel, so that the GLP-1 receptor stimulant semeglutide can be used for treating the hippocampal mitochondrial autophagy. The glial cell phenotype is regulated to be converted from a proinflammatory state to an anti-inflammatory state, and the cognitive impairment is improved. The invention determines a new medicine application method for linking the semeglutide with hippocampal pathology reduction and cognitive function recovery, and has important significance on treatment of VaD.

The invention belongs to the technical field of biological medicine, and discloses a safe and efficient non-gene editing neural stem cell and application thereof in treatment of nervous system related diseases. The invention provides a non-gene-edited neural stem cell (hCiPSC-NSCs) derived from human induced pluripotent stem cells, the neural stem cell is obtained by reprogramming human umbilical cord mesenchymal stem cells through a small molecule compound (such as a TGF-beta / GSK-3beta inhibitor), exogenous gene introduction is not involved, and the neural stem cell has a normal karyotype, no tumorigenicity and relatively high safety; and the efficient implantation of the non-tumorigenicity hippocampal region is realized in three months. The neural stem cell can improve the autism-like phenotype of a VPA-exposed rat by targeting the intestinal-brain axis at the same time.

The invention relates to application of an exosome derived from olfactory mucosa mesenchymal stem cells pretreated based on active peptide in improvement of neuroinflammation, in particular to a treatment strategy for neuroinflammation of Alzheimer's disease (AD). An IFN-FGF fusion protein (SEQ ID NO: 3) and a coding gene (SEQ ID NO: 4) of the IFN-FGF fusion protein are constructed, and the IFN-FGF fusion protein and the coding gene (SEQ ID NO: 4) are used for in-vitro pretreatment of OM-MSCs, so that the A-MS Cs-Exo exosome with anti-inflammatory and neuroprotective functions is obtained. In an A beta oligomer-induced AD neuroinflammation model, the A-MSCs-Exo significantly alleviates neuroinflammation and cognitive impairment by inhibiting excessive activation of hippocampal Iba1 + microglia cells, reducing serum IL-6 level, improving SOD activity and improving Morris water maze behavioral performance, the effect is better than that of traditional FGF-1 pretreatment (B-MSCs-Exo) and untreated exosome (C-MSCs-Exo), and the A-MSCs-Exo can be used for preparing the A beta oligomer-induced AD neuroinflammation model. The invention provides a novel exosome intervention strategy for AD treatment.

The invention discloses Weissella sinus PD13 for improving Alzheimer's disease and application of the Weissella sinus PD13, and relates to the technical field of biological medicine. Experiments prove that Weissella cibaria PD13 can improve spatial learning and memory impairment and autonomous exploration ability of AD model mice in Alzheimer's disease model mice induced by brain injection of A beta oligomer, and alleviate damage of neurons in hippocampal regions of the Alzheimer's disease model mice, so that the effect of protecting neurons is achieved, and the Weissella cibaria PD13 can be used for preparing drugs for treating Alzheimer's disease. According to the present invention, the Weissella cibaricola can effectively prevent and treat the Alzheimer's disease, increase the glutathione content and the superoxide dismutase enzyme activity of the mouse serum, and reduce the malondialdehyde content, such that the Weissella cibaricola has good prevention and treatment effects on the Alzheimer's disease, and the new approach is provided for developing the Alzheimer's disease-related drugs.

The invention provides application of a probiotic-fructo-oligosaccharide-lycium ruthenicum microecological preparation for targeted hippocampal neuron repair in neuroprotection and a composite product, and relates to the technical field of microorganisms. The probiotic oligosaccharide composition provided by the invention comprises lycium ruthenicum powder, fructo-oligosaccharide and compound probiotic powder, the compound probiotic powder comprises plant lactobacillus, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis, and the probiotic composition provided by the invention can significantly improve the neuron morphology and arrangement of a hippocampus area of a model group; the neuron damage is reduced.

The invention relates to a targeted central nervous system engineered exosome capable of efficiently enriching RNAi as well as a preparation method and application of the targeted central nervous system engineered exosome. The invention particularly relates to a sorting signal for regulating and controlling RNAi to be enriched into the exosome, and the RNAi enriched into the exosome through the sorting signal can be effectively combined with beta-amyloid protein mRNA expressed in a central nervous system after reaching a cortex and a hippocampal region. The invention also relates to a chimera comprising the sorting signal and the RNAi, and an exosome enriched with the RNAi. The exosome can efficiently target a central nervous system through overexpressed SIRP alpha and MCAM, and the contained siRNA can inhibit the production of beta-amyloid protein mRNA.

The present invention relates to the technical field of microorganisms, in particular to the use of Lactobacillus plantarum JYLP-326 in the preparation of a product for improving mood. The Lactobacillus plantarum JYLP-326 is deposited in China General Microbiological Culture Collection Center on 27 June 2019, with the deposit address of Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number of CGMCC No.18038. The product for improving the mood contains the Lactobacillus plantarum JYLP-326. Experimental results show that the Lactobacillus plantarum JYLP-326 can significantly improve the low mood and depression tendency of chronic unpredictable mild stress (CUMS) model mice, adjust the levels of emotion-related nerve cells, proteins and inflammatory factor in hippocampus regions of the CUMS mice, and have a potential neuroprotective effect on the hippocampus regions of the mice.

The invention discloses a pharmaceutical composition for preventing and treating AD (Alzheimer's disease). The pharmaceutical composition is prepared from the following components in parts by weight: 50 to 100 parts of salidroside, 60 to 80 parts of protocatechuic acid, 70 to 80 parts of wedelolactone, 50 to 80 parts of apigenin, 30 to 60 parts of luteolin and 10 to 30 parts of oleanolic acid. The invention further discloses application of the pharmaceutical composition for preventing and treating AD as a central nervous protective agent. The behavioral, morphological and immunological experiments show that a mouse learning and memory disorder model can be successfully copied by intraperitoneal injection of D-gal, and the pharmaceutical composition and the positive drug can improve the structural morphology of neurons in a hippocampus region by improving the exploration ability, the working memory ability and the space exploration ability of a mouse on new things, so that the learning and memory disorder of the mouse can be successfully copied. The number of neurons in the hippocampus and the number of nissl's somes are increased, so that the neuroprotective effect on D-gal model mice is achieved, and experimental and theoretical basis is provided for clinical application of the pharmaceutical composition for preventing and treating AD and research and development of new anti-AD traditional Chinese medicines.